Stockreport

Structure Therapeutics (GPCR) Is Up 121.3% After Strong Phase 2b Data For Oral GLP-1 Aleniglipron - What's Changed [Yahoo! Finance]

Structure Therapeutics Inc. - American Depositary Shares  (GPCR) 
PDF Structure Therapeutics recently reported positive topline Phase 2b and related ACCESS program data for its oral GLP-1 agonist aleniglipron in adults with obesity or over [Read more]